197 related articles for article (PubMed ID: 32699065)
1.
Moore C; Monforte H; Teer JK; Zhang Y; Yoder S; Brohl AS; Reed DR
Cold Spring Harb Mol Case Stud; 2020 Aug; 6(4):. PubMed ID: 32699065
[TBL] [Abstract][Full Text] [Related]
2. TRIM28 haploinsufficiency predisposes to Wilms tumor.
Diets IJ; Hoyer J; Ekici AB; Popp B; Hoogerbrugge N; van Reijmersdal SV; Bhaskaran R; Hadjihannas M; Vasileiou G; Thiel CT; Seven D; Uebe S; Ilencikova D; Waanders E; Mavinkurve-Groothuis AMC; Roeleveld N; de Krijger RR; Wegert J; Graf N; Vokuhl C; Agaimy A; Gessler M; Reis A; Kuiper RP; Jongmans MCJ; Metzler M
Int J Cancer; 2019 Aug; 145(4):941-951. PubMed ID: 30694527
[TBL] [Abstract][Full Text] [Related]
3. TRIM28 variants and Wilms' tumour predisposition.
Hol JA; Diets IJ; de Krijger RR; van den Heuvel-Eibrink MM; Jongmans MC; Kuiper RP
J Pathol; 2021 Jul; 254(4):494-504. PubMed ID: 33565090
[TBL] [Abstract][Full Text] [Related]
4. Germline mutations and somatic inactivation of TRIM28 in Wilms tumour.
Halliday BJ; Fukuzawa R; Markie DM; Grundy RG; Ludgate JL; Black MA; Skeen JE; Weeks RJ; Catchpoole DR; Roberts AGK; Reeve AE; Morison IM
PLoS Genet; 2018 Jun; 14(6):e1007399. PubMed ID: 29912901
[TBL] [Abstract][Full Text] [Related]
5. Microdissecting the genetic events in nephrogenic rests and Wilms' tumor development.
Charles AK; Brown KW; Berry PJ
Am J Pathol; 1998 Sep; 153(3):991-1000. PubMed ID: 9736048
[TBL] [Abstract][Full Text] [Related]
6. Decreased E-cadherin expression correlates with higher stage of Wilms' tumors.
Safford SD; Freemerman AJ; Langdon S; Bentley R; Goyeau D; Grundy PE; Skinner MA
J Pediatr Surg; 2005 Feb; 40(2):341-8. PubMed ID: 15750927
[TBL] [Abstract][Full Text] [Related]
7. 16q heterozygosity loss in Wilms' tumour in children and its clinical importance.
Skotnicka-Klonowicz G; Rieske P; Bartkowiak J; Szymik-Kantorowicz S; Daszkiewicz P; Debiec-Rychter M
Eur J Surg Oncol; 2000 Feb; 26(1):61-6. PubMed ID: 10718182
[TBL] [Abstract][Full Text] [Related]
8. A unique subset of low-risk Wilms tumors is characterized by loss of function of TRIM28 (KAP1), a gene critical in early renal development: A Children's Oncology Group study.
Armstrong AE; Gadd S; Huff V; Gerhard DS; Dome JS; Perlman EJ
PLoS One; 2018; 13(12):e0208936. PubMed ID: 30543698
[TBL] [Abstract][Full Text] [Related]
9. Wilms tumour resulting from paternal transmission of a TRIM28 pathogenic variant-A first report.
Whitworth J; Armstrong R; Maher ER
Eur J Hum Genet; 2024 Mar; 32(3):361-364. PubMed ID: 38282073
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathologic correlates of loss of heterozygosity in Wilm's tumor: a preliminary analysis.
Grundy P; Telzerow P; Moksness J; Breslow NE
Med Pediatr Oncol; 1996 Nov; 27(5):429-33. PubMed ID: 8926924
[TBL] [Abstract][Full Text] [Related]
11. Identification of new Wilms tumour predisposition genes: an exome sequencing study.
Mahamdallie S; Yost S; Poyastro-Pearson E; Holt E; Zachariou A; Seal S; Elliott A; Clarke M; Warren-Perry M; Hanks S; Anderson J; Bomken S; Cole T; Farah R; Furtwaengler R; Glaser A; Grundy R; Hayden J; Lowis S; Millot F; Nicholson J; Ronghe M; Skeen J; Williams D; Yeomanson D; Ruark E; Rahman N
Lancet Child Adolesc Health; 2019 May; 3(5):322-331. PubMed ID: 30885698
[TBL] [Abstract][Full Text] [Related]
12. Genomic profiling maps loss of heterozygosity and defines the timing and stage dependence of epigenetic and genetic events in Wilms' tumors.
Yuan E; Li CM; Yamashiro DJ; Kandel J; Thaker H; Murty VV; Tycko B
Mol Cancer Res; 2005 Sep; 3(9):493-502. PubMed ID: 16179496
[TBL] [Abstract][Full Text] [Related]
13. Nephroblastoma (Wilms' tumor): a model system of aberrant renal development.
Re GG; Hazen-Martin DJ; Sens DA; Garvin AJ
Semin Diagn Pathol; 1994 May; 11(2):126-35. PubMed ID: 7809506
[TBL] [Abstract][Full Text] [Related]
14. Recent advances in Wilms' tumor predisposition.
Maciaszek JL; Oak N; Nichols KE
Hum Mol Genet; 2020 Oct; 29(R2):R138-R149. PubMed ID: 32412586
[TBL] [Abstract][Full Text] [Related]
15. Fine mapping of Wilms' tumors with 16q loss of heterozygosity localizes the putative tumor suppressor gene to a region of 6.7 megabases.
Safford SD; Goyeau D; Freemerman AJ; Bentley R; Everett ML; Grundy PE; Skinner MA
Ann Surg Oncol; 2003 Mar; 10(2):136-43. PubMed ID: 12620908
[TBL] [Abstract][Full Text] [Related]
16. 16q loss of heterozygosity and microsatellite instability in Wilms' tumor.
Mason JE; Goodfellow PJ; Grundy PE; Skinner MA
J Pediatr Surg; 2000 Jun; 35(6):891-6; discussion 896-7. PubMed ID: 10873032
[TBL] [Abstract][Full Text] [Related]
17. Loss of heterozygosity for chromosomes 16q and 1p in Wilms' tumors predicts an adverse outcome.
Grundy PE; Telzerow PE; Breslow N; Moksness J; Huff V; Paterson MC
Cancer Res; 1994 May; 54(9):2331-3. PubMed ID: 8162576
[TBL] [Abstract][Full Text] [Related]
18. Loss of heterozygosity at 7p in Wilms' tumour development.
Powlesland RM; Charles AK; Malik KT; Reynolds PA; Pires S; Boavida M; Brown KW
Br J Cancer; 2000 Jan; 82(2):323-9. PubMed ID: 10646884
[TBL] [Abstract][Full Text] [Related]
19. Amplification and overexpression of CACNA1E correlates with relapse in favorable histology Wilms' tumors.
Natrajan R; Little SE; Reis-Filho JS; Hing L; Messahel B; Grundy PE; Dome JS; Schneider T; Vujanic GM; Pritchard-Jones K; Jones C
Clin Cancer Res; 2006 Dec; 12(24):7284-93. PubMed ID: 17189400
[TBL] [Abstract][Full Text] [Related]
20. Loss of heterozygosity in Wilms' tumors, studied for six putative tumor suppressor regions, is limited to chromosome 11.
Mannens M; Devilee P; Bliek J; Mandjes I; de Kraker J; Heyting C; Slater RM; Westerveld A
Cancer Res; 1990 Jun; 50(11):3279-83. PubMed ID: 2159377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]